Adenocarcinoma of Esophagus: Diagnostic Workup and Treatment Approach
For suspected esophageal adenocarcinoma, initiate workup with upper endoscopy and biopsy, followed by CT chest/abdomen and endoscopic ultrasound (EUS) for staging; treatment depends on stage with endoscopic resection for T1a disease, neoadjuvant therapy plus surgery for locally advanced disease, and systemic chemotherapy with immunotherapy for metastatic disease.
Diagnostic Workup
Initial Evaluation
- Upper endoscopy with biopsy is the gold standard for diagnosis 1, 2
- Document precise tumor location, size, and extent
- Obtain multiple biopsies to confirm adenocarcinoma histology
Staging Investigations
For all confirmed cases:
- CT chest and abdomen for distant metastases 3
- Endoscopic ultrasound (EUS) is the most accurate modality for locoregional staging (T and N stage) 3
- Use miniprobe sonography if standard EUS cannot traverse tumor strictures
- Consider EUS-guided fine needle aspiration (FNA) for suspicious lymph nodes
- PET-CT may be added for detecting occult metastases, though not explicitly required by guidelines
Additional considerations:
- For proximal tumors near the tracheal bifurcation: bronchoscopy to exclude tracheobronchial invasion 3
- For adenocarcinomas: diagnostic laparoscopy with intra-abdominal ultrasound before planned esophagectomy to rule out occult peritoneal/hepatic metastases 3
Common Pitfall
Many patients undergo repeat gastroscopy after referral (32.2% in one study) 4. Ensure initial endoscopy includes precise anatomical mapping, tumor measurements, and distance from incisors to avoid unnecessary repeat procedures.
Treatment Approach by Stage
Early Stage Disease (T1a)
For T1a tumors (confined to mucosa):
- Endoscopic resection is the treatment of choice 5, 6
- Endoscopic mucosal resection (EMR) is acceptable for lesions ≤20 mm 7
- Endoscopic submucosal dissection (ESD) is preferred over EMR for lesions >20 mm to achieve en bloc resection 7
- Excellent prognosis with endoscopic therapy when no lymphovascular invasion present 1, 6
Critical decision point: If deep resection margins are involved or high-risk features present (lymphovascular invasion, poor differentiation, submucosal invasion >500 μm), proceed to esophagectomy with lymphadenectomy 5
Locally Advanced Resectable Disease (T2-T4a, N+)
The standard approach is multimodal therapy:
Preferred regimen options 5:
Neoadjuvant chemoradiotherapy (CROSS regimen) followed by surgery [Level I, A evidence]
- Weekly carboplatin-paclitaxel with 41.4 Gy radiation in 23 fractions
- Particularly effective for adenocarcinoma
Perioperative chemotherapy (FLOT regimen) followed by surgery [Level I, A evidence]
- Alternative to chemoradiotherapy with equivalent outcomes
Surgery:
- Radical transthoracic esophagectomy with en bloc two-field lymphadenectomy is the procedure of choice 5
- Ivor Lewis procedure (right thoracotomy) for distal tumors
- McKeown procedure (three-field) for mid/upper tumors
- Minimally invasive esophagectomy (MIO) offers lower morbidity, faster recovery, and better quality of life compared to open surgery with equivalent oncologic outcomes 5
Critical caveat: Even with complete clinical response to neoadjuvant therapy, patients must proceed to surgery—watch-and-wait strategies have insufficient evidence 5
Adjuvant therapy:
- For patients with residual pathological disease after neoadjuvant chemoradiotherapy (ypT1+ and/or ypN1+), administer adjuvant nivolumab [Level I, A; ESMO-MCBS score: A] 5
Metastatic or Unresectable Disease
Note: The provided guidelines focus primarily on squamous cell carcinoma for advanced disease. For esophageal adenocarcinoma, treatment should follow gastric cancer guidelines as per ESMO recommendations 5.
General principles for advanced adenocarcinoma:
- First-line platinum-fluoropyrimidine doublet chemotherapy
- Consider adding immunotherapy (pembrolizumab or nivolumab) based on PD-L1 expression and HER2 status (following gastric cancer protocols)
- Early palliative care referral and nutritional support are essential [Level I, A] 5
Follow-Up Strategy
Key principle: Regular surveillance after curative treatment does not improve survival except in specific scenarios 5
Recommended approach:
- Focus follow-up visits on symptom assessment, nutritional support, and psychosocial needs rather than routine imaging 5
- Multidisciplinary team involvement (dietician, gastroenterologist, psychologist) is often necessary
- 90% of relapses occur within first 2 years 5
Exception: For patients achieving complete response to definitive chemoradiotherapy, perform 3-month follow-up with endoscopy, biopsies, and CT scan to detect early recurrence amenable to salvage surgery 5